UY32769A - Composición para el tratamiento de la hiperplasia prostática benigna - Google Patents

Composición para el tratamiento de la hiperplasia prostática benigna

Info

Publication number
UY32769A
UY32769A UY0001032769A UY32769A UY32769A UY 32769 A UY32769 A UY 32769A UY 0001032769 A UY0001032769 A UY 0001032769A UY 32769 A UY32769 A UY 32769A UY 32769 A UY32769 A UY 32769A
Authority
UY
Uruguay
Prior art keywords
treatment
composition
benign prostate
prostate hyperplasia
hyperplasia
Prior art date
Application number
UY0001032769A
Other languages
English (en)
Inventor
Axel Niclas Petri
Erichsen Lars
Original Assignee
Ferring Int Ct Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Int Ct Sa filed Critical Ferring Int Ct Sa
Publication of UY32769A publication Critical patent/UY32769A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Composiciones que comprenden degarelix para el tratamiento de la hiperplasia prostática benigna (HPB)
UY0001032769A 2009-07-06 2010-07-07 Composición para el tratamiento de la hiperplasia prostática benigna UY32769A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09251738 2009-07-06
US23581609P 2009-08-21 2009-08-21

Publications (1)

Publication Number Publication Date
UY32769A true UY32769A (es) 2011-02-28

Family

ID=41112615

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032769A UY32769A (es) 2009-07-06 2010-07-07 Composición para el tratamiento de la hiperplasia prostática benigna

Country Status (18)

Country Link
US (2) US20110039787A1 (es)
EP (1) EP2451469B1 (es)
JP (1) JP2012532188A (es)
KR (1) KR20120038956A (es)
CN (1) CN102470159A (es)
AR (1) AR081439A1 (es)
AU (1) AU2010269958A1 (es)
BR (1) BR112012000185A2 (es)
CA (1) CA2766008A1 (es)
IL (1) IL216987A0 (es)
MX (1) MX2012000315A (es)
NZ (1) NZ597060A (es)
RU (1) RU2011152514A (es)
SA (1) SA110310575B1 (es)
TW (1) TW201105344A (es)
UY (1) UY32769A (es)
WO (1) WO2011004260A2 (es)
ZA (1) ZA201109513B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
CN102421414A (zh) * 2009-05-01 2012-04-18 辉凌公司 用于治疗前列腺癌的组合物
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
US9260480B2 (en) 2010-10-27 2016-02-16 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
EP2854831B1 (en) * 2012-06-01 2024-07-10 Ferring B.V. Manufacture of degarelix
HUP1400294A2 (hu) 2014-06-13 2015-12-28 Skillpharm Kft Clopidogrel új alkalmazása

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE593491T1 (de) * 1991-04-25 1994-11-17 Romano S.-Cergue Deghenghi LHRH-Antagonisten.
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5860957A (en) * 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
AR042815A1 (es) * 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
GB0506759D0 (en) * 2005-04-02 2005-05-11 Medical Res Council Combination treatment methods
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
JOP20090061B1 (ar) * 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
US8105292B2 (en) * 2008-02-11 2012-01-31 Safety Syringes, Inc. Reconstitution means for safety device
CN102421414A (zh) * 2009-05-01 2012-04-18 辉凌公司 用于治疗前列腺癌的组合物
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
US9260480B2 (en) * 2010-10-27 2016-02-16 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
EP2447276A1 (en) * 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) * 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
EP2731607B1 (en) * 2011-07-15 2017-10-11 Ferring B.V. Method for timing a colonoscopy wherein a picosulate composition is administered

Also Published As

Publication number Publication date
SA110310575B1 (ar) 2014-10-23
US20120172302A1 (en) 2012-07-05
EP2451469B1 (en) 2014-08-20
AU2010269958A1 (en) 2012-01-19
WO2011004260A3 (en) 2011-05-19
AR081439A1 (es) 2012-09-05
RU2011152514A (ru) 2013-08-20
EP2451469A2 (en) 2012-05-16
BR112012000185A2 (pt) 2017-06-13
WO2011004260A2 (en) 2011-01-13
IL216987A0 (en) 2012-02-29
KR20120038956A (ko) 2012-04-24
TW201105344A (en) 2011-02-16
ZA201109513B (en) 2012-09-26
MX2012000315A (es) 2012-02-13
JP2012532188A (ja) 2012-12-13
US20110039787A1 (en) 2011-02-17
NZ597060A (en) 2013-05-31
CN102470159A (zh) 2012-05-23
CA2766008A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
UY32769A (es) Composición para el tratamiento de la hiperplasia prostática benigna
CL2011000134A1 (es) Compuestos derivados de aminofenoxiindazoles, inhibidores de c-met; composicion farmaceutica que comprende a estos compuestos; y su uso para tratar el cancer.
ECSP11010798A (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
NZ622505A (en) Therapeutic compounds and compositions
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
CL2012000302A1 (es) Compuestos derivados de tubulisinas; compuestos conjugados que los comprenden; compuestos intermediarios; y uso para tratar el cancer.
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
GT200900027A (es) Compuestos organicos
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
ECSP11010787A (es) Compuestos orgánicos
HN2008001464A (es) Formulaciones para administrcion parenteral de compuestos y sus usos
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
BRPI0908127A2 (pt) Método para o tratamento do câncer da próstata com degarelix antagonista do gnrh
CR11629A (es) INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA- DESATURASA.
MX336022B (es) Activadores de pkm2 bicíclicos.
EA201170294A1 (ru) Способы лечения реперфузионных повреждений
ECSP077247A (es) Trans - clomifeno para el tratamiento de la hipertrofia prostatica benigna, cancer prostatico, hipogonodismo, trigliceridos elevados y alto colesterol
BR112012011823A2 (pt) métodos e composições para tratar tumores sólidos e outras malignidades
CO6341625A2 (es) Derivados de indol como agentes anticáncer
PA8792401A1 (es) Fenilendiaminas
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
EA201100882A1 (ru) Профилактическое/терапевтическое средство против рака
MX2009009197A (es) Mejora de respuesta a tension celular.
TN2011000013A1 (en) Amidophenoxyindazoles useful as inhibitors of c-met

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190211